Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Pfizer Makes Plans For Interchangeable Adalimumab Filing
Company Sees Double-Digit Growth In Biosimilars Business In Q3 FY21
Nov 09 2021
•
By
Akriti Seth
Pfizer aims to launch its Abrilada (adalimumab-afzb) biosimilar to Humira in 2023 • Source: Alamy
More from Biosimilars
More from Products
